Navigation Links
SomaLogic announces agreement with leading global pharma company to accelerate R&D
Date:10/18/2011

Boulder CO, October 18, 2011 SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts.

"We are excited by this opportunity to work with Novartis' world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics," said Larry Gold, CEO of SomaLogic. "We believe that our technology is uniquely able to address the significant drug discovery and development challenges currently faced by biopharmaceutical companies."

Terms of the agreement were not disclosed.

SomaLogic's proprietary proteomic platform is built on two decades of painstaking work to develop an entirely new generation of specific protein-binding reagents that would break open protein biomarker discovery and development in order to drive new diagnostic and therapeutic opportunities. At the heart of SomaLogic's technology are "SOMAmers" (Slow-Offrate Modified Aptamers), an entirely novel class of protein-binding reagents. SOMAmers offer a uniquely powerful combination of specific binding to individual proteins and facile nucleic acid-based quantification, allowing accurate detection and measurement of literally thousands of proteins over a vast range of concentrations in just a few drops of blood or other tissues.


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
617-816-9834
SomaLogic, Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
2. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
3. Trudeau Institute announces its latest discovery in the fight against tuberculosis
4. Biophysical Society announces 2012 Society Fellows
5. White House announces that 2 UCSB faculty members will receive US presidential science awards
6. FASEB announces new client: The Histochemical Society
7. MedNet Solutions Announces the Latest Release of iMedNet EDC
8. FASEB MARC program announces the travel award recipients for the 2011 Leadership Development and Grant Writing Seminar for graduate students, postdoctoral fellows and new assistant professors
9. Trudeau Institute announces new discovery in battle against infections
10. Wiley-Blackwell announces continued growth in impact factor journals
11. The Society for Nutrition Education (SNE) announces Helen Denning Ullrich Award of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology: